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Abstract. Undifferentiated febrile illnesses (UFIs) are common in low- and middle-income countries. We prospectively
investigated the causes of UFIs in 627 patients presenting to a tertiary referral hospital in Kathmandu, Nepal. Patients with
microbiologically confirmed enteric fever (218 of 627; 34.8%) randomized to gatifloxacin or ofloxacin treatment were
previously reported. We randomly selected 125 of 627 (20%) of these UFI patients, consisting of 96 of 409 (23%) cases
with sterile blood cultures and 29 of 218 (13%) cases with enteric fever, for additional diagnostic investigations. We found
serological evidence of acute murine typhus in 21 of 125 (17%) patients, with 12 of 21 (57%) patients polymerase chain
reaction (PCR)-positive for Rickettsia typhi. Three UFI cases were quantitative PCR-positive for Rickettsia spp., two UFI
cases were seropositive for Hantavirus, and one UFI case was seropositive for Q fever. Fever clearance time (FCT) for
rickettsial infection was 44.5 hours (interquartile range = 26–66 hours), and there was no difference in FCT between
ofloxacin or gatifloxacin. Murine typhus represents an important cause of predominantly urban UFIs in Nepal, and
fluoroquinolones seem to be an effective empirical treatment.
Undifferentiated febrile illnesses (UFIs) are a common
clinical problem in south Asia.1,2 Defined as a fever without
a focus of infection on initial physical examination or in basic
laboratory tests, UFIs represent a considerable burden of
disease with diagnostic and therapeutic challenges. Empirical
broad-spectrum antimicrobials are generally prescribed but
with little evidence-based guidance on likely etiologies or
potential treatment responses. Previous studies on UFIs,
including those originating from our research group in
Nepal,3–5 have been limited by a lack of molecular testing,
little convalescent serological testing, and few data on treat-
ment outcomes.
We sought to address this knowledge gap by expanding
investigations to determine further causes and treatment out-
comes of Nepalese patients with UFIs. Diagnostic tests were
performed for scrub typhus, murine typhus, Spotted Fever
Group (SFG) rickettsiosis, Q fever, leptospirosis, Hantavirus,
Brucella, and dengue (Table 1). The patients described in this
report were previously enrolled into a randomized, controlled
trial (RCT) comparing gatifloxacin with ofloxacin for treating
enteric fever in Patan Hospital, a 450-bed teaching hospital
within the Kathmandu Valley, Nepal. All patients had UFIs
at enrollment and came from predominantly urban regions;
the methods and results from patients with subsequent blood
culture-confirmed enteric fever have been reported previ-
ously.3 Briefly, patients were eligible to enter if they were
> 2 years old, had an untreated UFI for > 3 days, and could
be treated in the community. Each patient was randomly
assigned to 7 days of treatment with either gatifloxacin
(10 mg/kg per day in a single oral dose) or ofloxacin (20 mg/kg
per day in two divided oral doses). All patients were managed
as outpatients, with assessment of fever clearance time (FCT)
and collection of acute (day 1) and convalescent (day 30) blood
samples by trained community medical auxiliaries. Approval
for the study was obtained from the Nepal Health Research
Council and the Oxford Tropical Research Ethics Committee.
The trial was registered as ISRCTN 63006568. Written informed
consent was obtained from all study participants.
Between July of 2008 and August of 2011, 627 patients with
UFIs were enrolled in the RCT: 311 of 627 (49.6%) patients
received gatifloxacin, and 316 of 627 (50.4%) patients received
ofloxacin (Figure 1). Salmonella Typhi and Salmonella
Paratyphi A were cultured from the blood of 109 of 311
(35%) and 109 of 316 (34%) patients in each treatment arm,
respectively. The remaining 409 of 627 (65%) patients had
UFIs with negative blood cultures. Although no formal sam-
ple size calculation was carried out for this study, we ran-
domly selected 125 of 627 (20%) UFI patients for additional
diagnostic testing, consisting of 96 of 409 (23%) UFI patients
and 29 of 218 (13%) enteric fever patients (Salmonella Typhi,
N = 17; Salmonella Paratyphi A, N = 12) (Table 1).
All data were analyzed using Stata v13 (College Station, TX).
Kruskal–Wallis tests were used to compare clinical parameters
between the enteric fever and rickettsial groups. FCTs were
summarized by Kaplan–Meier estimates and compared between
groups using a Cox regression model with only one covariate.
All tests were performed using two-sided 5% significance.
In total, 21 of 125 (17%) patients were identified with acute
murine typhus infection on the basis of at least a fourfold
antibody titer rise from day 1 to day 30 (Figure 1); 10 of these
cases were confirmed by quantitative polymerase chain reac-
tion (PCR; ompB gene target), and 2 cases were confirmed by
conventional PCR/sequencing of the 17-kDa and/or gltA genes.
In total, 12 of 21 (57%) PCR-positive murine typhus cases
were confirmed. Three cases with a Rickettsia spp.-positive
quantitative PCR result could not be further differentiated
because of limited sample specimen. However, these speci-
mens have a high probability of being murine typhus cases
because of their positive R. typhi serology. The possibility
remains that SFG Rickettsia could be responsible for these
cases. None of the patients with rickettsial infections were
coinfected with Salmonella Typhi or Salmonella Paratyphi A.
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Additionally, two cases were serologically positive for Hanta-
virus, and one case was serologically positive for Q fever.
Although the study design allowed for limited comparison,
the clinical presentations and basic laboratory values, such as
complete blood count, liver function test, and creatinine, of
21 rickettsial patients and 29 enteric fever patients were, in
general, similar. However, the FCT was significantly pro-
longed in the enteric fever patients, with a median of 88 hours
(interquartile range [IQR] = 54–116), for both drugs com-
pared with the FCT in those with rickettsial infections, with
a median of 44.5 hours (IQR = 26–66; hazard ratio = 3.71;
P < 0.001).
Our study has a number of limitations. First, we were unable
to test the whole study population for alternative causes of
UFI, and the 20% proportion of patients selected may not have
been truly representative of the whole population. Second,
serological testing for Rickettsia may lack specificity, although
we defined acute infection as a greater than or equal to a
fourfold rise in reciprocal antibody titers between admission
and convalescence sera.
Despite these limitations, our study highlights that Rickettsia
spp. are an important cause of UFIs in Nepal6 and that these
patients present with similar clinical characteristics to enteric
fever. Although the original study was designed to enroll
typhoid patients and represents more of an urban population,
we detected a 17% murine typhus case rate and a possible 2%
Rickettsia spp. infection rate in a random subselection of the
study. Notably, we have evidence suggesting that Hantavirus
and Q fever contribute to UFIs. The absence of scrub typhus
is likely because of the predominantly urban patients enrolled
in this study.
The recommended therapy for murine typhus is doxycycline,7
although fluoroquinolones are known to be an effective alter-
native for the treatment of SFG rickettsioses.8 Without control
groups of untreated or doxycycline-treated patients, only ten-
tative conclusions can be drawn, but despite previous reports of
poor responses to ciprofloxacin in murine typhus9,10 our find-
ings suggest that gatifloxacin and ofloxacin may be effective
empirical treatment choices in Nepalese patients with UFIs.
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Table 1
Diagnostic tests used for the study
Organism/diagnostic tests Supplier Catalog number Diagnostic criteria
Methodological reference
or validation study Purpose
Orientia tsutsugamushi
IgM ELISA NMRC In house ³ 0.2 nett OD 11 Serological screening
IgG ELISA NMRC In house ³ 0.2 nett OD 11 Serological screening
IgM IFA ARRL RT-001 ³ Fourfold rising titer in
paired samples
12 Quantitative serological
confirmation
IgG IFA ARRL RT-001 ³ Fourfold rising titer in
paired samples
12 Quantitative serological
confirmation
Real-time PCR MORU In house 47-kDa gene amplification 13
R. typhi
IgM ELISA NMRC In house ³ 0.2 nett OD 11 Serological screening
IgG ELISA NMRC In house ³ 0.2 nett OD 11 Serological screening
IgM IFA ARRL RT-001 ³ Fourfold rising titer in
paired samples
12 Quantitative serological
confirmation
IgG IFA ARRL RT-001 ³ Fourfold rising titer in
paired samples
12 Quantitative serological
confirmation
Real-time PCR MORU In house ompB gene amplification 14 Confirmation of infection
Rickettsia spp.
Real-time PCR MORU In house 17-kDa gene amplification 13 Confirmation of infection
Coxiella burnetti
Phase II IgM ELISA Serion ESR1312M Manufacturer’s criteria Product insert Serological screening
Phase I/II IFA Fuller Manufacturer’s criteria Product insert Quantitative serological
confirmation
Hantavirus Puumala
IgM ELISA Serion ESR145M Manufacturer’s criteria Product insert Serological screening
Anti-Hantavirus IIFT
Mosaic II Test
Euroimmun Quantitative serological
confirmation
Leptospira
IgM ELISA Serion ESR125M Manufacturer’s criteria Product insert Serological screening
Microscopic
agglutination test*
QSHL In house ³ Fourfold rising titer in
paired samples
15 Quantitative serological
confirmation
Brucella spp.
Rose–Bengal NIAH In house Positive agglutination reaction 16 Serological screening
Dengue
SD NS1 Ag ELISA Alere 11EK50 Manufacturer’s criteria 17 Serological screening
ARRL = Australian Rickettsial Reference Laboratory; ELISA = enzyme-linked immunosorbent assay; IFA = indirect immunofluorescence assay; Ig = immunoglobulin; IIFT = indirect
immunofluorescence test; MORU = Mahidol Oxford Research Unit; nett OD = net optical density (net stands for the difference from baseline to measured values); NIAH = National Institute
of Animal Health–Thailand; NMRC = Naval Medical Research Centre; QSHL = Queensland State Health Laboratory; SD NS1 Ag = standard diagnostics non-structural protein number one
(refers to Dengue virus protein) antigen.
*Leptospira serovars tested: pomona, hardjo, tarassovi, grippotyphosa, celledoni, copenhageni, australis, pyrogenes, canicola, hebdomadis, sari, sarmin, autumnalis, cynopteri, ballum, bataviae,
djasiman, javanica, panama, shermani, and pohnpei.
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